Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Lasker Awards Given to Researchers in Virology, Physiology

By Stephanie Guzowski | September 13, 2016

The Albert and Mary Lasker Foundation today named seven scientists as winners of its annual awards, which honor basic medical research, clinical research and special achievement. Each category will receive $250,000.

The Lasker-DeBakey Clinical Medical Research Award went to two virologists — Ralf F. W. Bartenschlager of the University of Heidelberg in Germany and Charles M. Rice of Rockefeller University in New York — for creating a system to replicate the hepatitis C virus in the laboratory, and to Michael Sofia, an industry scientist, for using the system to develop the hepatitis C drug, now sold as Sovaldi.

Scientists first sequenced the genome of the hepatitis C virus in 1989. Researchers then believed they could insert that newly sequenced RNA into cultured cells and watch it replicate — but this approach was not so simple.

In the 1990s, Bartenschlager’s and Rice’s labs discovered a method to replicate fragments of the hepatitis C virus’s RNA in lab-grown cells. The researchers’ discoveries, which were published in journal articles in 1999 and 2000, happened after many failed attempts, since hepatitis C virus is well-known for being difficult to replicate in a lab setting.

Afterward, pharmaceutical researchers targeting hepatitis C used Bartenschlager’s and Rice’s replication method in the drug discovery process. In 2005, Sofia joined a small biotech company called Pharmasset, where he developed a chemical that blocked hepatitis C replication. His work led to the development of a new oral drug, sofosbuvir, marketed as Sovaldi. Sovaldi was approved by the FDA in 2013 to treat hepatitis C virus, which affects about 3.5 million Americans, and as many as 170 million people worldwide.

Sovaldi can cure patients, without severe side effects. Since Sovaldi was approved, other hepatitis C treatments have come on the market, including Gilead’s Harvoni, which has cure rates of 94 percent to 99 percent in eight to 12 weeks of therapy. Despite these successes, hepatitis drugs are high in price, with some between $54,000 and $94,000 for a full course of treatment.

A team of researchers from Harvard University, Johns Hopkins University, and the Francis Crick Institute were also honored for their discovery of the pathway by which human cells sense and adapt to changes in oxygen availability. Their work led to the discovery of a protein, HIF-1, that emerged when oxygen was scarce and then activated a large network of genes. Their discovery has had implications in treating heart disease and cancer.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50